Treatment of malignancy-associated hypercalcemia with norethisterone: a case report.

Abstract

Hypercalcemia is a common cause of morbidity in cancer patients. The mechanism of malignancy-associated hypercalcemia includes increased bone resorption and decreased renal calcium clearance which also occur in primary hyperparathyroidism. Norethisterone can inhibit bone resorption and has recently been shown to be effective treatment for mild hyperparathyroidism in post menopausal women. We report the successful use for the first time of norethisterone (5 mg daily) in a case of malignancy-associated hypercalcemia after other standard agents failed.

• Authors: C S Anderson, C L Olweny, A G Need
• Journal: Australian and New Zealand journal of medicine (Aust N Z J Med) Vol. 19 Issue 1 Pg. 51-4 (Feb 1989) ISSN: 0004-8291 [Print] Australia
• PMID: 2764805 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vincristine
• Cyclophosphamide
• Norethindrone
• Prednisone

Topics

• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Cyclophosphamide (therapeutic use)
• Female
• Humans
• Hypercalcemia (drug therapy, etiology)
• Middle Aged
• Neoplasms (complications)
• Norethindrone (therapeutic use)
• Prednisone (therapeutic use)
• Vincristine (therapeutic use)